0043 GMT - There's more pain ahead for Healius in pathology services, suggests Jefferies. Healius now expects underlying Ebitda of A$259 million-A$264 million in FY 2026. It cited lower pathology volumes and higher costs as the reason for lower than previously expected profitability. Analyst David Stanton expects Healius's underlying Ebit will total some A$31 million in FY 2026. That implies a pathology Ebit margin of around 2%, down 30 bps on a year earlier. "The outlook for growth in the pathology sector remains challenging--we continue to flag a decrease in FY 2026 net pathology funding of up to A$90 million," Jefferies says. "Healius is not immune to this." (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

May 13, 2026 20:43 ET (00:43 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.